Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
This article was originally published in PharmAsia News
Executive Summary
Usually, having more money that you know how to use is not considered a problem, but cash-rich Astellas may feel a bit stranded now that Gilead has trumped its bid to buy CV Therapeutics. But at least one analyst thinks the U.S. biotech sector still offers plenty of potential acquisitions for the Japanese pharma
You may also be interested in...
Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia
TOKYO - Japan's leading pharma companies have made a number of high profile M&A moves in the past two years, and there are no signs that they are done with their pursuits. However, the number of attractive biotechs at the right stage of growth and value has decreased drastically
Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia
TOKYO - Japan's leading pharma companies have made a number of high profile M&A moves in the past two years, and there are no signs that they are done with their pursuits. However, the number of attractive biotechs at the right stage of growth and value has decreased drastically
Astellas Forecasts Earnings Decline; Says Urology Franchise Will Drive Global Growth
Astellas recently reported declining sales, operating income and profits for fiscal year 2008 due to the appreciation of the yen and the revision of Japan's drug pricing policy. The decline in sales and earnings was the first to be posted since the 2005 merger between Fujisawa and Yamanouchi Pharmaceutical